SARS-CoV-2 Research Reagents
The SARS-CoV-2 structural proteins (1) spike (S), membrane (M), envelope (E), and nucleocapsid (N), serve as cytological markers for viral sites of infection including cell-to-cell transmissibility.
ProSci Inc. offers Antibodies validated by patient samples and Antibodies specific for Variants (Cat. No. 9359) as well as Antibodies Variant-Independent for cytological use – IHC, IF. For example, Spike Antibody, Cat. No. 3525, targets the conserved intracellular domain of the spike protein. This serves as a powerful reagent for use in IHC, ICC, and IF (2). Research reagents additionally include Antibodies against host factors ACE2 receptor, TMPRSS2, and furin (3).
SARS-CoV-2 Proteome
Select Your SARS-CoV-2 Target of Interest
The ORF1ab-encoded polyprotein is subsequently processed into 16 individual non-structural proteins (NSP) by two proteases PLpro/nsp3 and 3CLpro/nsp5. The 3’ half of ORF1ab, ORF1b, encodes a variety of enzymes critical for viral transcription and replication.
ProSci offers antibodies and recombinant proteins against all four structural proteins of SAR-CoV-2. Select your protein of interest:
Accessory proteins are important factors involved in the pathology of SARS-CoV-2. Most of the roles ascribed to these accessory proteins are related to immune evasion mechanisms like inhibition of cytokine secretion by ORF9c, or counteracting type I IFN action by ORF3b, ORF6, ORF7a, ORF8, or ORF9b (1). Explore ProSci's comprehensive list of SARS-CoV-2 accessory factor reagents:
SARS-CoV-2 Research Reagents
Select Your Antigen
More CoV Reagents
Viral Infectious Disease Reagents
Downloadable Resources
More Areas of SARS-CoV-2 Research
-
SARS-CoV-2 Pseudovirus Reagents
ProSci has developed SARS-CoV-2 pseudoviruses with a luciferase reporter, allowing researchers to quickly build their own neutralization and inhibitor interaction assays. These pseudoviruses have been engineered to lack the appropriate coding for the virus to replicate and express the necessary proteins of the respective virus to allow for rigorous experimental studies but lack the machinery to replicate. This makes pseudoviruses excellent research tools for labs operating under BSL-2 by offering an alternative to live-virus experimentation.
-
SARS-CoV-2 Variants Research Reagents
The use of the ProSci Spike Antibody (Cat. No. 3525) has been cited in numerous publications in 2020 and 2021. Of great interest now, while ProSci offers antibodies and recombinant proteins representing the full SARS-CoV-2 proteome, and host factors, the company also has a catalog of spike S1 antibodies to variant SARS-CoV-2 B.1.1.7 (Alpha) to the P681H point mutation (Cat. No. 9359) – this residue is adjacent to the Furin cleavage site, required for viral cell entry.
-
COVID-19 Patient Sample Validated Antibodies
ProSci enhances research efforts globally to understand this virus and its health effects. We have validated antibodies to all four structural proteins and several non-structural SARS-CoV-2 proteins by IHC with COVID-19-positive patient tissue samples, showing that these antibodies can detect the virus itself.
-
Single Domain Antibodies
ProSci offers recombinant single domain antibodies for SARS-CoV-2 Spike S1 and S2. Contact ProSci to discuss your sdAb target and detection needs.
-
Matched Pair Antibodies
ProSci offers SARS-CoV-2 antibody pairs validated by sandwich ELISA. These matched pair antibodies include antibodies against Spike S1, Spike RBD, and Nucleocapsid proteins. Some of the antibodies have been validated with COVID-19 patient samples.
SARS-CoV-2-related Citations
ProSci is continuing to dedicate time and effort to the research of the SARS-CoV-2 virus responsible for the COVID-19 pandemic. Our antibodies have been cited in the journals such as Cell, Nature Microbiology, The Journal of Vaccum Science and Technology B, and many more. Check out how ProSci antibodies and recombinant proteins were used in these studies, and how they can benefit you for yours!
References
- (1) Fehr AR, Perlman S. Coronaviruses: an overview of their replication and pathogenesis. Methods Mol Biol. 2015;1282:1–23. https://doi.org/10.1007/978-1-4939-2438-7_1
- (2) Singh, et al. Responses to acute infection with SARS-CoV-2 in the lungs of rhesus macaques, baboons, and marmosets. Nat Microbiol. 2021 Jan;6(1):73-86. DOI: 10.1038/s41564-020-00841-4. Epub 2020 Dec 18PMID: 33340034
- (3) Hoffmann, M., Kleine-Weber, H., Schroeder, S., et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. S0092–8674(20)30229–4 Advance online publication. https://doi.org/10.1016/j.cell.2020.02.052